61 active not recruiting. 61 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 61 | Active not recruiting 61 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment Gelclair Oral Mouth Rinse - Squamous Cell Carcinoma, Oropharyngeal Cancers | Phase 4 | Active not recruiting | McMaster University | 29 | 2025-12-15 | 2026-07-13 |
| Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis Rozanolixizumab - Myasthenia Gravis | Phase 4 | Active not recruiting | UCB Biopharma SRL | 40 | 2025-12-01 | 2026-10-29 |
| A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia Zanubrutinib - Waldenström's Macroglobulinemia | Phase 4 | Active not recruiting | BeiGene | 16 | 2025-10-17 | 2026-08-10 |
| Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy Semaglutide Pen Injector - Prostate Cancer | Phase 4 | Active not recruiting | Hamilton Health Sciences Corporation | 20 | 2025-07-02 | 2026-09-14 |
| A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma Teclistamab - Multiple Myeloma | Phase 4 | Active not recruiting | Johnson & Johnson Private Limited | 75 | 2025-05-22 | 2026-09-25 |
| Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer NALIRIFOX - Colorectal Cancer (CRC) | Phase 4 | Active not recruiting | Affiliated Cancer Hospital of Shantou University Medical College | 57 | 2025-05-15 | 2025-06-13 |
| COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer Darolutamide Oral Tablet, leuprorelin - Prostate Cancer | Phase 4 | Active not recruiting | Brazilian Clinical Research Institute | 144 | 2025-02-17 | 2026-10-30 |
| Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients Trastuzumab deruxtecan - BREAST CANCER | Phase 4 | Active not recruiting | AstraZeneca | 100 | 2025-01-02 | 2026-09-11 |
| Comparison of Inflammatory Factors, Pain Scale, and Postoperative Recovery Quality (QOR - 15) in Patients Undergoing Colorectal Cancer Surgery with Conventional General Anesthesia Techniques Compared to General Anesthesia Combined with Epidural Anesthesia At Prof. Ngoerah Hospital General Anesthesia (control group), General Anesthesia combined with epidural anesthesia - Inflammation Biomarkers, Quality of Recovery (QoR-15) | Phase 4 | Active not recruiting | Udayana University | 44 | 2024-12-28 | 2025-01-20 |
| A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis Efanesoctocog alfa - Haemophilia A (Moderate or Severe), Hemophilia, Classic | Phase 4 | Active not recruiting | Swedish Orphan Biovitrum | 37 | 2024-12-19 | 2026-04-30 |
| Impact of the Oral Microbiota on Relapse in HNSCC Patients buccal swabs - Head and Neck Cancer | Phase 4 | Active not recruiting | Institut Sainte Catherine | 100 | 2024-11-18 | 2025-02-04 |
| Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases Lorlatinib - Carcinoma, Non-Small-Cell Lung, Brain Metastases | Phase 4 | Active not recruiting | Guangdong Association of Clinical Trials | 41 | 2024-08-01 | 2026-04-09 |
| PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer 18F-rhPSMA-7.3, PET/CT - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 4 | Active not recruiting | Brigham and Women's Hospital | 20 | 2024-06-30 | 2026-10-29 |
| PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer Piflufolastat F 18 Intravenous Solution [PYLARIFY] - Prostate Cancer | Phase 4 | Active not recruiting | Lantheus Medical Imaging | 274 | 2024-02-08 | 2025-09-11 |
| Hepatoprotective Measures for Children at High Risk of NAFLD Ursodeoxycholic Acid 250 Mg Oral Capsule, Omega -3 fatty acids, Physical exercise - Non Alcoholic Fatty Liver Diseases (NAFLD), Obesity and Overweight | Phase 4 | Active not recruiting | Ain Shams University | 200 | 2023-11-19 | 2025-04-09 |
| Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan Trilaciclib, Placebo, Topotecan - Extensive-stage Small-cell Lung Cancer | Phase 4 | Active not recruiting | Pharmacosmos A/S | 302 | 2023-10-13 | 2026-10-05 |
| Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy PCV20 - Lymphoma | Phase 4 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2023-10-06 | 2026-09-15 |
| Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET Fluciclovine PET/CT - Prostate Cancer | Phase 4 | Active not recruiting | OHSU Knight Cancer Institute | 50 | 2023-10-04 | 2026-06-29 |
| First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients Olaparib, Bevacizumab - Carcinoma, Ovarian Epithelial | Phase 4 | Active not recruiting | Mario Negri Institute for Pharmacological Research | 190 | 2023-09-15 | 2026-06-25 |
| Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone XGEVA® - Giant Cell Tumor of Bone | Phase 4 | Active not recruiting | Amgen | 36 | 2023-08-17 | 2025-10-01 |
Showing 20 of 61. Sign in to see all of them.
Breast Neoplasms (7) · Prostatic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Head and Neck Neoplasms (3) · Multiple Myeloma (3) · Carcinoma, Hepatocellular (2) · Cardiotoxicity (2) · Cardiovascular Diseases (2) · Dementia (2) · Diabetes Mellitus (2) · Dupuytren Contracture (2) · Glioblastoma (2) · Glioma (2)
Neoplasms by Site (36) · Neoplasms by Histologic Type (25) · Hemic and Lymphatic Diseases (15) · Immune System Diseases (12) · Skin and Connective Tissue Diseases (12) · Hematologic Diseases (11) · Genital Diseases (10) · Immunoproliferative Disorders (10) · Lymphoproliferative Disorders (10) · Pathological Conditions, Signs and Symptoms (10) · Skin Diseases (10) · Urogenital Diseases (10) · Digestive System Diseases (9) · Endocrine System Diseases (9)
Dexamethasone (3) · Anesthesia, Epidural (2) · Atorvastatin (2) · Cisplatin (2) · Denosumab (2) · Gels (2) · Letrozole (2) · Prednisone (2) · lorlatinib (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Abiraterone Acetate (1) · Aminolevulinic Acid (1) · Analgesia (1) · Anastrozole (1) · Anesthesia, General (1)
Novartis Pharmaceuticals (4) · M.D. Anderson Cancer Center (3) · Ottawa Hospital Research Institute (3) · Helsinki University Central Hospital (2) · Pfizer (2) · AbbVie (1) · Affiliated Cancer Hospital of Shantou University Medical College (1) · Ain Shams University (1) · Almirall, S.A. (1) · Amgen (1) · AstraZeneca (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · BeiGene (1) · Biotech Pharmaceutical Co., Ltd. (1) · Brazilian Clinical Research Institute (1)
United States (20) · China (14) · Italy (12) · Canada (10) · France (10) · Spain (10) · Taiwan (8) · Australia (6) · Japan (6) · Poland (6) · Russia (6) · Brazil (5) · India (5) · South Korea (5) · Sweden (5)
Aleksi RP Reito, M.D., Ph.D., adjunct professor (1) · Alexandre Cochet (1) · Anna Ng-Pellegrino, MD (1) · Antti OV Malmivaara, M.D., Ph.D., adjunct professor (1) · Darryl Leong, MBBs,MPH,PhD,FRACP,FESC (1) · David VanderWeele, M.D., M.P.H. (1) · Dian Wang, MD (1) · Dong-Xin Wang, MD, PhD (1) · Fareed Khawaja, MD (1) · Fatma SE Ebeid, Professor of pediatrics (1)
PMID 20660041, PMID 21486711, PMID 21804697, PMID 23275102, PMID 24533710, PMID 25311218, PMID 30821848, PMID 30959948, PMID 31539308, PMID 32022887, PMID 32818460, PMID 34244284, PMID 35403447, PMID 36116420, PMID 36413436, PMID 36748942, PMID 37012015, PMID 38346307, PMID 38506889, PMID 39548016, PMID 39988204, PMID 41334972, PMID 42670961
2023 (2), 2014 (1), 2016 (1)